Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- Check4 days agoChange DetectedVersion bump: v3.0.2 replaces v3.0.1. The 'Back to Top' element was removed.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check19 days agoChange DetectedThe web page has updated its facility name and location details, specifically emphasizing the treatment options for Cholangiocarcinoma, including pembrolizumab and peginterferon alfa-2b.SummaryDifference2%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.